Inquis Medical, a leading innovator in venous thromboembolic disease treatment, today announced completion of patient ...

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...

There are no direct trials comparing these different forms of treatment. Each has shown reasonable efficacy as detailed in the literature below. Conventional management of acute DVT is based upon ...

Inquis Medical announced today that it completed enrollment in a pivotal trial evaluating its Aventus thrombectomy system.

Report on how AI is driving market transformation - The global heparin market  size is estimated to grow by USD 3.34 billion from 2024-2028, according to Technavio. The market is estimated to grow at ...

Patients with DVT, PE, or DVT and PE had higher annualized ... Early detection and appropriate treatment of this high-risk population have the potential for both clinical and economic benefits.

AngioDynamics, Inc. (ANGO), a New York-based medical technology company Monday announced the publication of results from the Acute ...

If you suddenly feel short of breath and a bit anxious, it might be something called "dyspnea." Let's dive into what the ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins. See ...

We have compiled some of the more recent heartbreaking stories of much-missed animals who have sadly died at Colchester Zoo in years gone by.

Hennion & Walsh Asset Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 33.8% during the ...

Inquis Medical, which is developing therapies for venous thromboembolic diseases, announced the completion of patient ...